Shots:

• The P-III TOPAZ-1 trial evaluates Imfinzi + CT vs PBO + CT in 685 patients with unresectable advanced or metastatic BTC at 145 centers across 17 countries including the US- EU- South America & several countries in Asia
• In a predefined interim analysis- IDMC has concluded that a trial met its 1EPs i.e.- improvement in OS & also showed an improvement in PFS & ORR in 2EPs. The combination was well tolerated & had a similar safety profile
• Imfinzi is also approved in the US- EU- Japan- China & multiple other countries globally for ES-SCLC based on the P-III CASPIAN trial. The therapy is being evaluated as a monothx. & in combinations with other anti-cancer treatments for multiple cancers

 ­ | Ref: AstraZeneca | Image: Mint